Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Sebti

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Biochemistry|August 20, 1996
Cys102 and His398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolaseZ Pei, S M Sebti
Expert Opinion on Investigational Drugs|November 28, 2000
Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesS M Sebti, A D Hamilton
Expert Opinion on Investigational Drugs|July 2, 2005
Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug developmentS M Sebti, A D Hamilton
Biochemical Society Transactions|August 1, 1996
Rational design of Ras prenyltransferase inhibitors as potential anticancer drugsS M Sebti, A D Hamilton
Pharmacology & Therapeutics|January 1, 1997
Inhibition of Ras prenylation: a novel approach to cancer chemotherapyS M Sebti, A D Hamilton
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
BleomycinsJ S Lazo, S M Sebti
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1997
BleomycinJ S Lazo, S M Sebti
Biochemistry|January 27, 1987
Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidasesS M Sebti, J S Lazo
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
BleomycinsJ S Lazo, S M Sebti
Oncogene|June 28, 2001
Design of growth factor antagonists with antiangiogenic and antitumor propertiesS M Sebti, A D Hamilton
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Biochemistry|August 20, 1996
Cys102 and His398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolaseZ Pei, S M Sebti
Expert Opinion on Investigational Drugs|November 28, 2000
Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesS M Sebti, A D Hamilton
Expert Opinion on Investigational Drugs|July 2, 2005
Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug developmentS M Sebti, A D Hamilton
Biochemical Society Transactions|August 1, 1996
Rational design of Ras prenyltransferase inhibitors as potential anticancer drugsS M Sebti, A D Hamilton
Pharmacology & Therapeutics|January 1, 1997
Inhibition of Ras prenylation: a novel approach to cancer chemotherapyS M Sebti, A D Hamilton
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
BleomycinsJ S Lazo, S M Sebti
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1997
BleomycinJ S Lazo, S M Sebti
Biochemistry|January 27, 1987
Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidasesS M Sebti, J S Lazo
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
BleomycinsJ S Lazo, S M Sebti
Oncogene|June 28, 2001
Design of growth factor antagonists with antiangiogenic and antitumor propertiesS M Sebti, A D Hamilton
Pageof 11